We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+12.81%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.16B
AUM Growth
-$275M
Cap. Flow
-$405M
Cap. Flow %
-18.73%
Top 10 Hldgs %
51.11%
Holding
71
New
13
Increased
14
Reduced
14
Closed
16

Top Buys

Rank Stock Value
1
GH icon
Guardant Health
GH
+$43.1M
2
EDIT icon
Editas Medicine
EDIT
+$30.1M
3
AXSM icon
Axsome Therapeutics
AXSM
+$28.3M
4
ANIP icon
ANI Pharmaceuticals
ANIP
+$22.8M
5
TVTX icon
Travere Therapeutics
TVTX
+$22.2M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$158M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$69.5M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$66.3M
4
BIIB icon
Biogen
BIIB
+$55.6M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$45.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
51
Heron Therapeutics
HRTX
$93.4M
$2.42M 0.11%
2,086,704
-1,148,018
-35% -$2.05M
KYNB
52
CALL
Kyntra Bio
KYNB
$27.4M
$2.06M 0.1%
+30,588
New +$12.7M
ALLK
53
DELISTED
Allakos
ALLK
$995K 0.05%
228,277
-3,356,723
-94% -$15.1M
IMUX icon
54
Immunic
IMUX
$178M
$774K 0.04%
30,831
-221,593
-88% -$3.71M
INKT icon
55
MiNK Therapeutics
INKT
$51.7M
$682K 0.03%
+32,487
New +$651K
ACRS icon
56
Aclaris Therapeutics
ACRS
$715M
– –
-1,708,971
Closed -$13.8M
ARGX icon
57
PUT
argenx
ARGX
$55.2B
– –
-100,000
Closed -$37.3M
BIIB icon
58
Biogen
BIIB
$30.9B
– –
-200,000
Closed -$55.6M
ETNB
59
PUT
DELISTED
89bio
ETNB
– –
-4,400
Closed -$67K
EXEL icon
60
Exelixis
EXEL
$13.9B
– –
-1,931,874
Closed -$37.5M
NKTX icon
61
Nkarta
NKTX
$152M
– –
-1,354,200
Closed -$4.81M
QURE icon
62
uniQure
QURE
$2.75B
– –
-865,767
Closed -$17.4M
TSVT
63
DELISTED
2seventy bio
TSVT
– –
-350,000
Closed -$3.57M
DCPH
64
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-1,363,201
Closed -$21.1M
IMGN
65
PUT
DELISTED
Immunogen Inc
IMGN
– –
-428,100
Closed -$1.64M
SGEN
66
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-217,800
Closed -$44.1M
RETA
67
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-729,000
Closed -$66.3M
KDNY
68
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-3,000,000
Closed -$69.5M
DICE
69
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-1,600,000
Closed -$45.8M
ISEE
70
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-6,500,000
Closed -$158M
JNCE
71
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-4,259,653
Closed -$7.88M
1 2
3

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Deep Track Capital held 71 positions worth $2.16B, down 11% from $2.43B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Deep Track Capital withdrew a net $405M in Q2 2023, closing 16 positions and reducing 14 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $158M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier.

Against the trend, Deep Track Capital opened a new position in Guardant Health worth $53.7M.

  • Deep Track Capital's largest Q2 2023 buy was Guardant Health: 1,500,000 shares worth $53.7M.
  • Deep Track Capital added most to Travere Therapeutics in Q2 2023, an estimated $22.2M increase.
  • Deep Track Capital's biggest Q2 2023 reduction was Immunovant, cutting an estimated $37.5M.
  • Deep Track Capital fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $158M.
  • Deep Track Capital's ten largest holdings make up 51% of its $2.16B portfolio in Q2 2023.
  • Deep Track Capital opened 13 new positions and closed 16 in Q2 2023.
  • Deep Track Capital's portfolio value fell 11% quarter-over-quarter to $2.16B.

Based on Deep Track Capital's 13F filing for Q2 2023, filed 14 Aug 2023.